Journal ArticleDOI
Global Cancer Incidence and Mortality Rates and Trends—An Update
Reads0
Chats0
TLDR
Applied cancer control measures are needed to reduce rates in HICs and arrest the growing burden in LMICs, as well as for lung, colorectal, breast, and prostate cancer, although some low- and middle-income countries (LMIC) now count among those with the highest rates.Abstract:
There are limited published data on recent cancer incidence and mortality trends worldwide. We used the International Agency for Research on Cancer's CANCERMondial clearinghouse to present age-standardized cancer incidence and death rates for 2003-2007. We also present trends in incidence through 2007 and mortality through 2012 for select countries from five continents. High-income countries (HIC) continue to have the highest incidence rates for all sites, as well as for lung, colorectal, breast, and prostate cancer, although some low- and middle-income countries (LMIC) now count among those with the highest rates. Mortality rates from these cancers are declining in many HICs while they are increasing in LMICs. LMICs have the highest rates of stomach, liver, esophageal, and cervical cancer. Although rates remain high in HICs, they are plateauing or decreasing for the most common cancers due to decreases in known risk factors, screening and early detection, and improved treatment (mortality only). In contrast, rates in several LMICs are increasing for these cancers due to increases in smoking, excess body weight, and physical inactivity. LMICs also have a disproportionate burden of infection-related cancers. Applied cancer control measures are needed to reduce rates in HICs and arrest the growing burden in LMICs.read more
Citations
More filters
Journal ArticleDOI
Cancer treatment and survivorship statistics, 2016.
Kimberly D. Miller,Rebecca L. Siegel,Chun Chieh Lin,Angela B. Mariotto,Joan L. Kramer,Julia H. Rowland,Kevin Stein,Rick Alteri,Ahmedin Jemal +8 more
TL;DR: The number of cancer survivors continues to increase because of both advances in early detection and treatment and the aging and growth of the population and for the public health community to better serve these survivors, the American Cancer Society and the National Cancer Institute collaborate to estimate the number of current and future cancer survivors.
Journal ArticleDOI
Occurrence of the potent mutagens 2- nitrobenzanthrone and 3-nitrobenzanthrone in fine airborne particles
TL;DR: In the present study, 2-NBA, 3-NBA and selected PAHs and Nitro-PAHs were determined in fine particle samples collected in a bus station and an outdoor site, showing low cancer risk incidence and incremental lifetime cancer risk (ILCR) calculated for both places.
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara,Yung-Jue Bang,Satoru Iwasa,Naotoshi Sugimoto,Min-Hee Ryu,Daisuke Sakai,Hyun-Cheol Chung,Hisato Kawakami,Hiroshi Yabusaki,Jeeyun Lee,Kaku Saito,Yoshinori Kawaguchi,Takahiro Kamio,Akihito Kojima,Masahiro Sugihara,Kensei Yamaguchi,DESTINY-Gastric Investigators +16 more
TL;DR: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based lin...
Journal ArticleDOI
Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.
Douglas E. Wood,Ella A. Kazerooni,Scott Baum,Georgie A. Eapen,David S. Ettinger,Lifang Hou,David M. Jackman,Donald Klippenstein,Rohit Kumar,Rudy P. Lackner,Lorriana E. Leard,Inga T. Lennes,Ann N. Leung,Samir S. Makani,Pierre P. Massion,Peter J. Mazzone,Robert E. Merritt,Bryan F. Meyers,David E. Midthun,Sudhakar Pipavath,Christie Pratt,Chakravarthy Reddy,Mary E. Reid,Arnold J. Rotter,Peter B. Sachs,Matthew B. Schabath,Mark L. Schiebler,Betty C. Tong,William D. Travis,Benjamin Wei,Stephen C. Yang,Kristina M. Gregory,Miranda Hughes +32 more
TL;DR: This manuscript focuses on identifying patients at high risk for lung cancer who are candidates for low-dose computed tomography of the chest and on evaluating initial screening findings.
References
More filters
Journal ArticleDOI
Helicobacter pylori and esophageal cancer risk: a meta-analysis.
Farhad Islami,Farin Kamangar +1 more
TL;DR: The results suggest an inverse association between CagA-positive H. pylori colonization and risk of EAC, which may be partly responsible for the recent increase in EAC incidence in Western countries.
Journal ArticleDOI
Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database.
TL;DR: The contrast between the time differences in implementation of mammography screening and the similarity in reductions in mortality between the country pairs suggest that screening did not play a direct part in the reductions in breast cancer mortality.
Journal ArticleDOI
Gastric cancer: epidemiology and risk factors.
TL;DR: The current understanding of the worldwide burden of this disease, its geographic variation, and temporal trends are summarized, and Helicobacter pylori infection is focused on as the most important factor in noncardia gastric cancer.
Journal ArticleDOI
Recent developments in esophageal adenocarcinoma
TL;DR: Esophageal adenocarcinoma (EAC) is characterized by 6 striking features: increasing incidence, male predominance, lack of preventive measures, opportunities for early detection, demanding surgical therapy and care, and poor prognosis as mentioned in this paper.
Journal ArticleDOI
Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010
Benjamin O. Anderson,Eduardo Cazap,Nagi S. El Saghir,Cheng Har Yip,Hussein M. Khaled,Isabel V. Otero,Clement Adebamowo,Rajendra A. Badwe,Joe B. Harford +8 more
TL;DR: The biggest challenges identified for low-income countries were little community awareness that breast cancer is treatable, inadequate advanced pathology services for diagnosis and staging, and fragmented treatment options, especially for the administration of radiotherapy and the full range of systemic treatments.